ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

166
Analysis
Health CareHong Kong
Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.
more
Refresh
07 Apr 2024 14:06

China Healthcare Weekly (Apr.6) - Boom of TCM Injections Is Coming, Defects in GLP-1s, Sino Biopharm

Payment policy relaxation will drive rapid sales growth of TCM injection.GLP-1 has defects-patients will lose not only fat but also muscle. Mr...

Logo
391 Views
Share
09 Oct 2023 08:55

China's Weight Loss Drug Market – The Investment Opportunities and the Risks Behind

The GLP-1 target has been recognized as a blockbuster target, which has attracted great enthusiasm from investors.We analyzed related investment...

Logo
374 Views
Share
25 Feb 2022 06:15

Greater China Funds: China Health Care Reversal

Greater China managers have actively rebalanced portfolios away from China & HK Health Care over the last 6-months, with Taiwan Tech the key...

Logo
324 Views
Share
26 May 2024 10:05

Hong Kong Connect Flows (May 24th): BOC, CCB, ICBC, Zto Express, Tencent, Meituan, Xiaomi, CNOOC

We analyzed southbound Hong Kong connect flows in the past week and highlight flows for BOC, CCB, ICBC, Zto Express, Tencent, Meituan, Xiaomi, CNOOC.

Logo
318 Views
Share
24 May 2024 10:25

Akeso Biopharma Placement (9926.HK) - Would Investors Be Willing to Take a Gamble?

Stock price plunged today because the clinical data of AK112 (EGFRm NSCLC progressed after EGFR-TKI treatment) missed expectations. As we analyzed...

Logo
759 Views
Share
x